standard 8 - homepage.ntu.edu.twhomepage.ntu.edu.tw/~ntuidrec/file/2008tb/tb03.pdf · 2008/8/21 1...

2008/8/21

1

結核病藥物副作用的處理結核病藥物副作用的處理

台北醫學大學․市立萬芳醫院

結核病中心余明治醫師結核病中心余明治醫師

Standard 8• All patients who have not been treated previously • All patients who have not been treated previously

should receive an internationally accepted first-linetreatment regimen using drugs of known bioavailability

• The initial phase should consist of two months of isoniazid, rifampicin, pyrazinamide, and ethambutol

• The preferred continuation phase consists of • The preferred continuation phase consists of isoniazid and rifampicin given for four months

2008/8/21

2

新病人的藥物選擇、使用劑量與治療時間

• INH + RMP + EMB + PZA 2個月，再INH + RMP + EMB 4個月

• 一般使用劑量（每日）：

– Isoniazid：通常給予 300 mg，但如果體重過輕，可依體重調整劑量，大人為 5 mg/kg，孩童為 10-15 mg/kg

– Ethambutol：一般體重病人給予800 mg

– Rifampin：50 kg以上病人給予600 mg，50 kg以下病人給予450 mg

– Pyrazinamide：45 kg以下病人給予1000 mg，46-75 kg病人給予1500 mg，76 kg以上病人給予2000 kg

– Rifater：成人每10 kg給1錠，至多給5錠

– Rifinah：成人50 kg以上給Rifinah300 2錠，50 kg以下給

Rifinah150 3錠

2008/8/21

3

Risk Groups/Factors for Adverse Antituberculous Drug Reactions

• Advanced age• Malnutrition• Pregnancy• Alcoholism• Liver failure• Chronic renal failure• HIV infection• Disseminated and advanced TB• Atopy• Atopy• Anaemia• Diabetes mellitus• Family history of adverse anti-TB drug reactions• Patients receiving irregular anti-TB treatment• Patients receiving medication for other disorders,

in addition to anti-TB drugs

Age Transition of Tuberculosis Patients in Taiwan, 1957–2001

2006 >65y/o: 52% J Formos Med Assoc 2006;105:25–30

2008/8/21

4

Between July 2002 and December 2003

Male, 69 y/o

• Treatment regimen• Treatment regimen– Rifater+ EMB

• Skin rash and itching• GOT: 75 U/L, GPT:125 U/L• Uric acid: 15.7 mg/dl

2008/8/21

5

Rifater(Rifampin 120mg, INH 80mg, Pyrazinamide 250mg)衛肺特糖衣錠

皮膚發疹或癢、腸胃不適、

肢體麻刺感、肝功能異常

(食慾不振或黃疸)、關節酸痛

※橙色尿(正常現象)

Cycloserine(Cycloserine) 250mg惠絲菌素膠囊

皮膚發疹或紅斑、情緒低落、頭暈、頭痛、倦怠(少見) 、誘發癲癇(少見)

藥物劑量可能副作用藥物劑量可能副作用

請勿自行停藥，若有身體不舒服時，敬請立即回診或聯絡醫師、護理師及藥師協助處理!抗結核藥物

Rifinah150 mg(Rifampin 150mg, INAH 100mg)樂肺寧糖衣錠150


肢體麻刺感、肝功能異常(食慾

不振或黃疸) ※橙色尿(正常現象)

Rifinah300 mg(Rifampin 300mg, INAH 150mg)樂肺寧糖衣錠300


肢體麻刺感、肝功能異常(食慾

不振或黃疸) ※橙色尿(正常現象)

Mide 500mg/tab(Pyrazinamide , PZA)邁得錠

肝功能異常(食慾不振或黃疸)、

關節酸痛、皮膚發疹或癢、

腸胃不適

INAH 100mg/tab(Isoniazid)

肢體麻刺感、肝功能異常

Cravit 500mg/tab(Levofloxacin)可樂必妥

頭痛(暈) 、皮膚發疹或癢、

腸胃不適

※不可與胃藥、牛奶合用

Tubax 250mg/tab(Prothionamide)畢癆疾糖衣錠

噁心、嘔吐、疲倦、頭痛(暈)、

肝功能異常(食慾不振或黃疸)、

肢體麻刺感(少見)、

情緒抑鬱(少見)、視覺模糊(少見)

PAS 500mg/tab(P-aminosalicylic acid)鈣派斯膜衣錠

噁心、嘔吐、皮膚發疹或紅斑、

肝功能異常(食慾不振或黃疸)

(Isoniazid)肺速淨片 (食慾不振或黃疸) 、食慾不振、

皮膚發疹或癢

Rifampicin 150mg/cap(Rifampin , RIF)立汎黴素膠囊


肝功能異常(食慾不振或黃疸)

※橙色尿(正常現象)

Myambutol 400mg/tab (Ethambutol ,EMB) 孟表多錠

視覺模糊、皮膚發疹或癢、

腸胃不適

Avelox (Moxifloxacin, 400 mg)威洛速錠

噁心、嘔吐、疲倦、虛弱、

皮膚紅疹、關節腫脹疼痛(肌腱發炎,少見)※不可與胃藥合用

Streptomycin 1gm/vial(Streptomycin ,SM)鏈黴素

聽力受損、耳鳴、腎毒性、暈眩

Kanamycin 1gm/vial(Kanamycin ,KM)健黴素

聽力受損、耳鳴、腎毒性、暈眩

台北醫學大學‧萬芳醫學中心 97.02.B 祝您早日康復！結核病中心/藥劑部謹製

下列何種藥物會產生肝毒性？

• Rifater • Rifater – Isoniazid– Rifampin– Pyrazinamide

• Ethambutol

• GOT: 100 U/L• GPT: 162 U/L

2008/8/21

6

Isoniazid• Asymptomatic elevation of aminotransferasesAsymptomatic elevation of aminotransferases

– Elevations up to five times the upper limit of normal: 10–20%– Usually return to normal even with continued administration of the drug

• Clinical hepatitis: the risk increases• Increasing age: < 20 y/o: uncommon; 50–64 y/o: 2%• Underlying liver disease• Heavy alcohol consumption• Heavy alcohol consumption

• Fatal hepatitis– Associated with continued administration of INH despite onset of

symptoms of hepatitis

Isoniazid: Peripheral Neurotoxicity• Dose relatedDose related• Uncommon (< 0.2%) at

conventional doses• The risk is increased

– Associated with neuropathy• Nutritional deficiency• Diabetes• HIV infection• HIV infection• Renal failure• Alcoholism

– Pregnant and breastfeeding women

• Pyridoxine supplementation

2008/8/21

7

Isoniazid

• Central nervous system effects• Central nervous system effects– such as dysarthria, irritability, seizures, dysphoria, and

inability to concentrate• Lupus-like syndrome• Hypersensitivity reactions: such as fever, rash, Stevens-

Johnson syndrome hemolytic anemia vasculitis andJohnson syndrome, hemolytic anemia, vasculitis, andneutropenia are rare

Rifampin (RIF): Orange Discoloration of Bodily Fluids (sputum, urine, sweat, tears)

2008/8/21

8

Rifampin (RIF)

• HepatotoxicityHepatotoxicity– Transient asymptomatic hyperbilirubinemia

• May occur in 0.6% of patients– More severe clinical hepatitis

• Typically: a cholestatic pattern

Rifampin (RIF)

• Cutaneous reactions • Cutaneous reactions ( Pruritis with or without rash): 6% – Generally self-limited– Continued treatment with

the drug may be possible– More severe, occurring in

0.07–0.3% of patients

2008/8/21

9

Rifampin (RIF)

• Gastrointestinal reactions (nausea anorexia abdominal • Gastrointestinal reactions (nausea, anorexia, abdominal pain)– Rarely severe enough to necessitate discontinuation of the

drug• Flu-like syndrome

– More likely to occur with intermittent administration of a yhigher dose

• Severe immunologic reactions: (rare < 0.1%)– Thrombocytopenia, hemolytic anemia, acute renal failure

Rifampin (RIF)

• Drug interactions due to induction of hepatic • Drug interactions due to induction of hepatic microsomal enzymes– Reductions in serum concentrations of common

drugs• Such as oral contraceptives, methadone, and warfarin

Bidi ti l i t ti b t if i d – Bidirectional interactions between rifamycins and antiretroviral agents

2008/8/21

10

下列何種藥物會導致痛風發作？


• Ethambutol

Pyrazinamide• Hepatotoxicity: about 1%Hepatotoxicity: about 1%• Gastrointestinal symptoms: common• Nongouty polyarthralgia: may occur in up to 40% of patients

– The pain usually responds to aspirin or other nonsteroidal antiinflammatory agents

• Asymptomatic hyperuricemiaAn expected effect of the drug– An expected effect of the drug

– Generally without adverse consequence• Acute gouty arthritis

– Rare except in patients with preexisting gout • Transient morbilliform rash: usually self-limited

2008/8/21

11

下列何種藥物可能會導致病患視力減弱，甚至完全喪失？


• Ethambutol

Ethambutol

• Retrobulbar neuritis• Retrobulbar neuritis– Decreased visual acuity or red-green color discrimination– Dose related

• Minimal risk at a daily dose of 15 mg/kg• In patients with renal insufficiency

• Peripheral neuritis– A rare adverse effect

• Cutaneous reactions– Skin reactions requiring discontinuation of the drug occur in

0.2–0.7 % of patients

2008/8/21

12

Fixed-Dose Combination Preparations

• Reducing the risk of • Reducing the risk of monotherapy

• The ease of administration

• The potential for reducing medication reducing medication errors

2008/8/21

13

Streptomycin

• Ototoxicity (vestibular and hearing disturbances)• Ototoxicity (vestibular and hearing disturbances)– Most important adverse reaction– The risk is increased

• Age • Increasing single doses • The cumulative dose (especially above 100–120 g)

• Neurotoxicity– Circumoral parasthesias immediately after injection

• Nephrotoxicity

GOT: 777 U/L GPT: 1333 U/L

2008/8/21

14

Baseline Evaluations

• Measurements of AST bilirubin alkaline phosphatase and Measurements of AST, bilirubin, alkaline phosphatase, and serum creatinine and a platelet count should be obtained for all adults (uric acid and sugar)

• Testing of visual acuity and color vision should be performed when EMB is to be used

• All patients with tuberculosis have counseling and testing for HIV infection (U S )infection (U.S.)

•使用藥物前應安排血液及生化檢查，建議項目如下：CBC、AST/ALT、Bilirubin、Uric Acid、BUN/Cre。

Follow-Up Evaluations (1)

• It is essential that patients have clinical evaluations at It is essential that patients have clinical evaluations at least monthly – To identify possible adverse effects of the anti-TB

medications – To assess adherence

•為能確實掌握病人服藥順服度，診療醫師應鼓•為能確實掌握病人服藥順服度，診療醫師應鼓勵病人接受DOT，觀察用藥，尤其不應以開立慢性病連續處方箋的方式減少病人回診追蹤的頻率。

2008/8/21

15


• It is not necessary to monitor liver or renal function or • It is not necessary to monitor liver or renal function or platelet count for patients being treated with first-line drugs unless there were abnormalities at baseline or there are clinical reasons to obtain the measurements – Patients who have stable abnormalities of hepatic or renal

function at baseline should have repeat measurements early in the course of treatment, then less frequently to ensure that there has not been worsening

•使用藥物後的第2、4、8週均應追蹤檢查


• Patients receiving EMB should bePatients receiving EMB should be– Questioned regarding visual disturbances at monthly

intervals– Monthly repeat testing of visual acuity and color

vision is recommended for• Receiving an EMB dose exceeding 15--20 mg/kg• Receiving the drug for more than 2 months

•使用Ethambutol病人，應按月檢查視力及辨色力。

2008/8/21

16

T b l i Ch thTuberculosis ChemotherapyStill a Double-edged Sword

Am J Respir Crit Care Med 2003; 167: 1461–2

Transmission

2008/8/21

17

To Assess the Risk-Benefit of Anti-TB Drugs

Anti-TB chemotherapy: Three Basic Principles

• Multiple drugs to which the organisms are susceptible• Multiple drugs to which the organisms are susceptible• The drugs must be taken regularly• Therapy must continue for a sufficient period of time

ATS/CDC Am J Respir Crit Care Med 1994; 149: 1359-74

• Six-month regimens 2HERZ/4HR– 2HERZ/4HR

• Nine-month regimen – 2HER/7HR

ATS/CDC/IDSA Am J Respir Crit Care Med 2003; 167: 603–62

2008/8/21

18

Alternative Regimens (1)

• The potential role of a fluoroquinolone and optimal length of therapy have not been defined

ATS/CDC/IDSA Am J Respir Crit Care Med 2003; 167: 603–62

Building a Treatment Regimen for MDR-TB

2008/8/21

19

Alternative Regimens (2)

• Treatment becomes greatly complicated when any of • Treatment becomes greatly complicated when any of the first-line drugs cannot be used– Must only be cared by specialist physicians

• If pyrazinamide (Z) cannot be used: 2HRE/7HR• If isoniazid (H) cannot be used: 2REZ/10RE• If rifampicin (R) cannot be used: 2HEZ(S)/10HE

If th b t l (E) t b d 2HRZS/4HR• If ethambutol (E) cannot be used: 2HRZS/4HR

各類結核病人的治療建議簡表

病人分類建議治療方式藥物抗藥

或已知藥敏

試驗結果之

藥物副作用

單一藥物抗藥 1. INH不能用：EMB + RMP + PZA 6-9個月（治療2個月時痰培養陽性，治療9個月） 2. RMP不能用：INH + EMB + PZA ± FQN／INH + EMB + FQN 18個月（其中INH + EMB + PZA ± FQN至少2個月） 3. EMB不能用：優先 INH + RMP + PZA 2個月／INH + RMP 4個月

其次 INH + RMP 9個月 4. PZA不能用：INH + RMP 9個月二種以上藥物抗藥 1 INH + RMP不能用：EMB+PZA+FQN+TBN+SM 至少6個月／EMB + PZA + FQN + TBN12 18個月 1. INH + RMP不能用：EMB+PZA+FQN+TBN+SM 至少6個月／EMB + PZA + FQN + TBN12-18個月 2. INH + RMP + EMB/PZA/SM不能用：FQN+TBN+ PAS/CS + KM/AM，加EMB/PZA中可用者至少6個月，再FQN + TBN +

PAS/CS，加EMB/PZA中可用者12-18個月 3. INH + EMB不能用：RMP + PZA + FQN 9個月 4. RMP + EMB不能用：INH + PZA + FQN + SM 6個月／INH + PZA + FQN 12個月 5. EMB + PZA不能用：INH + RMP 9個月 6. INH + PZA不能用：RMP + EMB + FQN 9個月 7. RMP + PZA不能用：INH + EMB + FQN + SM 6個月／INH + EMB + FQN 12個月

2008/8/21

20

Management of Common Adverse Effects

• Attuned to the potential for adverse effects• Attuned to the potential for adverse effects– First-line drugs not be stopped without adequate

justification• Mild adverse effects

– Can generally be managed with symptomatic therapy• More severe effects

– Drugs must be discontinued

The Management Approach to Adverse Drug Reactions (1)

• With regards to the anti-TB treatment regimen With regards to the anti-TB treatment regimen following an adverse reaction– As many first-line drugs should be tried as possible

• More effective and less toxic than the second-line agents• Early detection is essential

– Clearly affect the associated morbidity and mortalityClearly affect the associated morbidity and mortality• Most adverse reactions are attributable to a single drug

– Can be resolved by designing a treatment regimen to exclude that agent

2008/8/21

21

The Management Approach to Adverse Drug Reactions (2)

• Evaluating the severity of the adverse reaction and establishing Evaluating the severity of the adverse reaction and establishing whether it is dose dependent– Making the necessary dose adjustments

• Mild or moderate adverse reactions– To provide symptomatic treatment for the reaction, adjust the drug dose,

or change the timing of administration– If these measures prove to be unsuccessful, suspension of treatment p , p

should then be considered• A serious adverse reaction

– All treatment should be suspended

Management of Drug-related Hepatitis (1)

• The first-line antituberculosis drugs INH RIF and PZA • The first-line antituberculosis drugs, INH, RIF, and PZA, can cause drug-induced liver injury

• An asymptomatic increase in AST concentration occurs in nearly 20% of patients treated with the standard four-drug regimen– In most patients asymptomatic aminotransferase elevations In most patients, asymptomatic aminotransferase elevations

resolve spontaneously– In addition to AST elevation, occasionally there are

disproportionate increases in bilirubin and alkaline phosphatase • This pattern is more consistent with rifampin hepatotoxicity

2008/8/21

22


• If AST levels are more than five times the upper limit of normal If AST levels are more than five times the upper limit of normal (with or without symptoms) or more than three times normal in the presence of symptoms– hepatotoxic drugs should be stopped immediately and the patient

evaluated carefully• Drug-induced hepatitis is usually a diagnosis of exclusion

– Serologic testing for hepatitis A, B, and C should be performedg g p , , p– Carefully regarding symptoms suggestive of biliary tract disease– Exposures to other potential hepatotoxins, particularly alcohol and

hepatotoxic medications


• To give at least three nonhepatotoxic anti-TB drugs • To give at least three nonhepatotoxic anti-TB drugs – Until the specific cause of hepatotoxicity can be determined

and an appropriate longer term regimen begun• Restarted one at a time

– After the AST concentration returns to less than two times the upper limit of normal

– In patients with elevated baseline AST from preexisting liver disease, drugs should be restarted when the AST returns to near baseline levels

• RIF: restarted first

2008/8/21

23


•治療改為併用SM、EMB、或Quinolone等兩種•治療改為併用SM、EMB、或Quinolone等兩種以上抗結核藥物

–肝功能恢復後，依INH→RMP→PZA順序，再重新進行小量漸進式給藥試驗

• If RIF and INH are tolerated and hepatitis was severe If RIF and INH are tolerated, and hepatitis was severe, PZA should be assumed to be responsible and should be discontinued

Gastrointestinal UpsetNausea, Vomiting, Poor Appetite, Abdominal Pain

• Many of the antituberculosis drugs can cause • Many of the antituberculosis drugs can cause gastrointestinal upset– Particularly in the first few weeks of therapy– Serum AST and bilirubin should be measured

• The initial approach to gastrointestinal pp gintolerance, not associated with hepatic toxicity – To change the hour of drug administration and/or to

administer the drugs with food

2008/8/21

24

Drug Administration• The first-line anti-TB medications should be administered

t th i l d th th i di id d d together as single dose rather than in divided doses • Ingestion with food delays or moderately decreases the

absorption of anti-TB drugs– The effects of food are of little clinical significance

• The wide therapeutic margin of the first-line agents

• Epigastric distress or nausea with the first-line drugs– Dosing with food is recommended

• Preferable to splitting a dose or changing to a second-line drug – Antacids have minimal effects on the absorption of the first-line anti-TB

drugs

Rash• All drugs used in treating tuberculosis can cause a rashAll drugs used in treating tuberculosis can cause a rash• The rash may be minor (affecting a limited area or being

predominantly manifested as itching)– Antihistamines should be given for symptomatic relief– All anti-TB medications can be continued

• If there is a generalized erythematous rash (especially if it is associated with fever and/or mucous membrane involvement)– All drugs should be stopped immediately – When the rash is substantially improved

• The medications can be restarted one by one

2008/8/21

25

發生結核藥物副作用的處理原則 (1)

•結核藥物副作用無法獲得妥善處理是病人不能•結核藥物副作用無法獲得妥善處理是病人不能按規服藥的主要原因

–診療醫師如對其副作用掉以輕心、或草率處理，往往會使病人對治療失去信心、斷續用藥，導致續發性抗藥性菌株的產生，後果非常嚴重。

–因此病人抱怨的副作用，無論如何微不足道、對身體無傷無論多麼千奇百怪匪夷所思只要足以體無傷；無論多麼千奇百怪、匪夷所思，只要足以影響病人服藥意願，診療醫師即應認真面對。


•該副作用是否嚴密觀察即可，不必停藥？•該副作用是否嚴密觀察即可，不必停藥？

–無症狀、AST／ALT 5倍以內的輕度上昇，或血球輕微減少。

–輕微的皮膚搔癢。

–初用藥時的全身倦怠，可予心理支持，或改睡前服藥。

–血清尿酸濃度在13 mg/dL以下時，請病人多喝水，暫不停藥，也不用降尿酸藥物。

2008/8/21

26


•該副作用可否症狀治療緩解，不必停藥？•該副作用可否症狀治療緩解，不必停藥？

–病人發生腸胃不適症狀，可將藥物改飯後服用，或併用Primperan等來緩解。

–輕度皮膚搔癢，可開立長效抗組織胺劑來緩解。

–輕度痛風、關節酸痛，先以短暫非類固醇抗發炎藥物（NSAID）作症狀處理。

–使用Isoniazid病人的末梢神經麻木，可以Pyridoxine緩解。

發生結核藥物副作用的處理原則 (4A)

•下列副作用應即停止用藥：下列副作用應即停止用藥–有肝炎症狀、AST/ALT 3倍以上的上昇，或無肝炎症狀、

AST/ALT 5倍以上的上昇。–嚴重之貧血、血小板下降、泛血球寡少症，及急性腎功能受

損、紫斑。

–嚴重無法緩解之痛風症狀、或血清尿酸值高於13mg/dL無法改善、或高血清尿酸症併急性腎功能惡化。

嚴重無法緩解之皮疹搔癢或併發St J h d–嚴重無法緩解之皮疹、搔癢、或併發Steven-Johnson syndrome。

–視力模糊。

–其他任何導致病人無法規則服藥的副作用、或不適反應。

2008/8/21

27

發生結核藥物副作用的處理原則 (4B)

•結核病人於治療中如發生此類藥物副作用時•結核病人於治療中如發生此類藥物副作用時

–除非該副作用非常明確是由某一特定結核藥物所致（如視力模糊之於Ethambutol、高血清尿酸之於Pyrazinamide），可以直接停止該藥

–建議先停止所有可能造成此副作用之結核藥物，俟副作用消失後，以逐一緩慢嘗試用藥方式（R h ll ）找出導致此副作用之藥物（Rechallenge）找出導致此副作用之藥物

Male, 63 y/o, DM (1)

• DST: all susceptible• DST: all susceptible• Treatment

– HERZS+Rifabutin+Moxifloxacin

• Skin rash, fever and liver function abnormalitiesfunction abnormalities

• ???

2008/8/21

28

Male, 63 y/o, DM (2)• 95/10/19 Isolation95/10/19 Isolation

– Symptomatic treatment• 95/10/23: INH 100 mg qd• 95/10/24: INH 300 mg qd

• 95/10/26: PZA 500 mg qd• 95/10/28: PZA 1500 mg qd

95/10/19 95/11/6 95/11/10 95/11/17 GOT 25 112 97 30 GPT 17 125 168 35

95/12/1 96/1/26 96/3/23 96/5/18 95/10/28: PZA 1500 mg qd

• 95/10/31: RIF 150 mg qd• 95/11/1: RIF 450 mg qd

GOT 30 23 22 26 GPT 27 13 14 20

Male, 56 y/o, Uremia

• GOT: 1704 U/L• GOT: 1704 U/L• GPT: 1481 U/L

2008/8/21

29

Male, 56 y/o, Uremia

Thank You for Your Attention !

standard 8 - homepage.ntu.edu.twhomepage.ntu.edu.tw/~ntuidrec/file/2008tb/tb03.pdf · 2008/8/21 1...

Documents